These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28710004)

  • 1. Development of PEGylated carboxylic acid-modified polyamidoamine dendrimers as bone-targeting carriers for the treatment of bone diseases.
    Yamashita S; Katsumi H; Hibino N; Isobe Y; Yagi Y; Kusamori K; Sakane T; Yamamoto A
    J Control Release; 2017 Sep; 262():10-17. PubMed ID: 28710004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated Serine-Modified Polyamidoamine Dendrimer as an Osteoid Surface-Targeting Drug Carrier.
    Yamashita S; Katsumi H; Sakane T; Yamamoto A
    Mol Pharm; 2022 Jul; 19(7):2573-2582. PubMed ID: 35666687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. l-Serine-modified polyamidoamine dendrimer as a highly potent renal targeting drug carrier.
    Matsuura S; Katsumi H; Suzuki H; Hirai N; Hayashi H; Koshino K; Higuchi T; Yagi Y; Kimura H; Sakane T; Yamamoto A
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10511-10516. PubMed ID: 30249662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers.
    Kojima C; Regino C; Umeda Y; Kobayashi H; Kono K
    Int J Pharm; 2010 Jan; 383(1-2):293-6. PubMed ID: 19761822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendrimer-based micelles with highly potent targeting to sites of active bone turnover for the treatment of bone metastasis.
    Yamashita S; Katsumi H; Shimizu E; Nakao Y; Yoshioka A; Fukui M; Kimura H; Sakane T; Yamamoto A
    Eur J Pharm Biopharm; 2020 Dec; 157():85-96. PubMed ID: 33039547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of efficient gene delivery systems by grafting pegylated alkylcarboxylate chains to PAMAM dendrimers: Evaluation of transfection efficiency and cytotoxicity in cancerous and mesenchymal stem cells.
    Ayatollahi S; Hashemi M; Oskuee RK; Salmasi Z; Mokhtarzadeh A; Alibolandi M; Abnous K; Ramezani M
    J Biomater Appl; 2015 Nov; 30(5):632-48. PubMed ID: 26265706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis.
    Yamashita S; Katsumi H; Hibino N; Isobe Y; Yagi Y; Tanaka Y; Yamada S; Naito C; Yamamoto A
    Biomaterials; 2018 Feb; 154():74-85. PubMed ID: 29120820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chondrocyte affinity peptide modified PAMAM conjugate as a nanoplatform for targeting and retention in cartilage.
    Hu Q; Chen Q; Yan X; Ding B; Chen D; Cheng L
    Nanomedicine (Lond); 2018 Apr; 13(7):749-767. PubMed ID: 29528264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma.
    Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y
    Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGylated Polyamidoamine dendrimer conjugated with tumor homing peptide as a potential targeted delivery system for glioma.
    Jiang Y; Lv L; Shi H; Hua Y; Lv W; Wang X; Xin H; Xu Q
    Colloids Surf B Biointerfaces; 2016 Nov; 147():242-249. PubMed ID: 27518456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyethylene glycol modified PAMAM dendrimer delivery of kartogenin to induce chondrogenic differentiation of mesenchymal stem cells.
    Hu Q; Ding B; Yan X; Peng L; Duan J; Yang S; Cheng L; Chen D
    Nanomedicine; 2017 Oct; 13(7):2189-2198. PubMed ID: 28579434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis.
    Yamashita S; Katsumi H; Sakane T; Yamamoto A
    J Drug Target; 2018 Nov; 26(9):818-828. PubMed ID: 29376757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
    Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
    J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer.
    Kojima C; Yao J; Nakajima K; Suzuki M; Tsujimoto A; Kuge Y; Ogawa M; Matsumoto A
    Int J Pharm; 2024 Jun; 659():124193. PubMed ID: 38703934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents].
    Kong SY; Tang GT; Pei YY; Jiang YY
    Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAMAM dendrimers: blood-brain barrier transport and neuronal uptake after focal brain ischemia.
    Santos SD; Xavier M; Leite DM; Moreira DA; Custódio B; Torrado M; Castro R; Leiro V; Rodrigues J; Tomás H; Pêgo AP
    J Control Release; 2018 Dec; 291():65-79. PubMed ID: 30308255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.
    Lu Y; Han S; Zheng H; Ma R; Ping Y; Zou J; Tang H; Zhang Y; Xu X; Li F
    Int J Nanomedicine; 2018; 13():5937-5952. PubMed ID: 30323584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers.
    Zhong Q; Humia BV; Punjabi AR; Padilha FF; da Rocha SRP
    Eur J Pharm Sci; 2017 Nov; 109():86-95. PubMed ID: 28774811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
    Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
    J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers.
    Mahmoudi A; Jaafari MR; Ramezanian N; Gholami L; Malaekeh-Nikouei B
    Int J Pharm; 2019 Jun; 564():77-89. PubMed ID: 30991135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.